

Carolyn M Bennett

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2809691/publications.pdf>

Version: 2024-02-01

33
papers

1,229
citations

566801

15
h-index

500791

28
g-index

33
all docs

33
docs citations

33
times ranked

1177
citing authors

#	ARTICLE	IF	CITATIONS
1	T-follicular helper cell expansion and chronic T-cell activation are characteristic immune anomalies in Evans syndrome. <i>Blood</i> , 2022, 139, 369-383.	0.6	14
2	Quality of life is an important indication for secondâ€line treatment in children with immune thrombocytopenia. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29023.	0.8	4
3	Phase 3 randomised trial of eltrombopag versus standard first-line pharmacological management for newly diagnosed immune thrombocytopenia (ITP) in children: study protocol. <i>BMJ Open</i> , 2021, 11, e044885.	0.8	2
4	Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28888.	0.8	7
5	Introducing a Novel Biophysical Platelet Function Panel to Investigate Disorders of Primary Hemostasis and Bleeding of Unknown Cause. <i>Blood</i> , 2021, 138, 2072-2072.	0.6	1
6	Standardizing the Diagnostic and Therapeutic Approach to Newly Diagnosed Children with ITP: An ITP Consortium of North America (ICON) Quality Improvement Initiative. <i>Blood</i> , 2021, 138, 755-755.	0.6	1
7	Severe Pediatric COVID-19 Presenting With Respiratory Failure and Severe Thrombocytopenia. <i>Pediatrics</i> , 2020, 146, e20201437.	1.0	40
8	Fatigue is common in paediatric immune thrombocytopenia and improves with secondâ€line treatments. <i>British Journal of Haematology</i> , 2020, 191, 15-16.	1.2	1
9	Longâ€term safety and sustained efficacy for up to 5Âyears of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the Bâ€YOND extension study. <i>Haemophilia</i> , 2020, 26, e262-e271.	1.0	28
10	Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study. <i>Blood Advances</i> , 2020, 4, 2451-2459.	2.5	67
11	Dealing with a critical national shortageâ€Approaches to triaging immune globulin supply in pediatric hematology and oncology. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28260.	0.8	8
12	Secondâ€line treatments in children with immune thrombocytopenia: Effect on platelet count and patientâ€centered outcomes. <i>American Journal of Hematology</i> , 2019, 94, 741-750.	2.0	37
13	A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children. <i>Blood</i> , 2019, 134, 2369-2369.	0.6	7
14	Increased Platelet Force Is Associated with Decreased Bleeding Severity in Pediatric Immune Thrombocytopenia. <i>Blood</i> , 2019, 134, 1096-1096.	0.6	0
15	Physician decision making in selection of secondâ€line treatments in immune thrombocytopenia in children. <i>American Journal of Hematology</i> , 2018, 93, 882-888.	2.0	30
16	Predictors of remission in children with newly diagnosed immune thrombocytopenia: Data from the Intercontinental Cooperative ITP Study Group Registry II participants. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26736.	0.8	51
17	ITP in Childhood: Predictors of Disease Duration. , 2018, , 223-239.		0
18	Fc-independent immune thrombocytopenia via mechanomolecular signaling in platelets. <i>Blood</i> , 2018, 131, 787-796.	0.6	54

#	ARTICLE	IF	CITATIONS
19	Early Prophylaxis Provides Continued Joint Protection in Severe Hemophilia A: Results of the Joint Outcome Continuation Study. <i>Blood</i> , 2018, 132, 382-382.	0.6	5
20	Single-platelet nanomechanics measured by high-throughput cytometry. <i>Nature Materials</i> , 2017, 16, 230-235.	13.3	88
21	Health Related Quality of Life and Fatigue Improve on Second Line Treatments in Pediatric Immune Thrombocytopenia (ITP). <i>Blood</i> , 2017, 130, 752-752.	0.6	2
22	Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1407-1413.	0.8	70
23	Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. <i>Lancet, The</i> , 2016, 388, 45-54.	6.3	116
24	Genes Influencing the Development and Severity of Chronic ITP Identified through Whole Exome Sequencing. <i>Blood</i> , 2015, 126, 73-73.	0.6	6
25	Clinical Outcomes in Children with Hemophilia B Treated Long Term with rFIXc: Interim Results of the B-YOND Extension Study. <i>Blood</i> , 2015, 126, 1093-1093.	0.6	0
26	Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group (ICIS). <i>Blood</i> , 2013, 121, 4457-4462.	0.6	87
27	The North American Chronic Immune Thrombocytopenia Registry (NACIR): Demographics and Treatment Responses. <i>Blood</i> , 2010, 116, 2509-2509.	0.6	0
28	One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab. <i>Pediatric Blood and Cancer</i> , 2009, 52, 259-262.	0.8	51
29	Chronic Immune Thrombocytopenia in Children: Epidemiology and Clinical Presentation. <i>Hematology/Oncology Clinics of North America</i> , 2009, 23, 1223-1238.	0.9	15
30	Female monozygotic twins discordant for hemophilia A due to nonrandom X-chromosome inactivation. <i>American Journal of Hematology</i> , 2008, 83, 778-780.	2.0	56
31	Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura. <i>Blood</i> , 2008, 112, 4003-4008.	0.6	171
32	Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. <i>Blood</i> , 2006, 107, 2639-2642.	0.6	204
33	Targeted ITP strategies: Do they elucidate the biology of ITP and related disorders?. <i>Pediatric Blood and Cancer</i> , 2006, 47, 706-709.	0.8	6